| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 698.51% | Oppenheimer | $8 → $3 | Maintains | Outperform |
| 08/10/2023 | 565.42% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 07/31/2023 | 565.42% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 06/28/2023 | 565.42% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 02/08/2023 | 565.42% | HC Wainwright & Co. | → $2.5 | Reiterates | → Buy |
| 11/08/2022 | 565.42% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 08/16/2022 | 964.68% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 06/23/2022 | 2561.7% | Oppenheimer | $12 → $10 | Maintains | Outperform |
| 06/23/2022 | 1230.85% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 06/01/2021 | 1763.19% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 12/18/2020 | 3094.04% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 12/17/2020 | 3094.04% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 09/10/2020 | 2029.36% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
What is the target price for Medicenna Therapeutics (MDNA)?
The latest price target for Medicenna Therapeutics (NASDAQ: MDNA) was reported by Oppenheimer on August 14, 2023. The analyst firm set a price target for $3.00 expecting MDNA to rise to within 12 months (a possible 698.51% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medicenna Therapeutics (MDNA)?
The latest analyst rating for Medicenna Therapeutics (NASDAQ: MDNA) was provided by Oppenheimer, and Medicenna Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Medicenna Therapeutics (MDNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medicenna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medicenna Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Medicenna Therapeutics (MDNA) correct?
While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a maintained with a price target of $8.00 to $3.00. The current price Medicenna Therapeutics (MDNA) is trading at is $0.38, which is out of the analyst's predicted range.
